U.S. Stocks in Motion | Clinical-stage biotechnology company Aspen Neuroscience (ASPE.US) debuts on the U.S. stock market, with shares falling more than 17% after the opening.

Zhito Finance APP has learned that on Friday, Aspen Neuroscience (ASPE.US) debuted on the U.S. stock market. As of press time, the stock fell more than 17% to $12.345. The IPO price was $15. Aspen Neuroscience is a clinical-stage biotechnology company headquartered in San Diego, California, founded in 2018, focused on using stem cell technology to develop innovative therapies for neurodegenerative diseases such as Parkinson's disease. The company's core product sasineprocel (ANPD001) is a stem cell therapy cultivated using the patient's own cells, designed to replace damaged or lost dopaminergic neurons in Parkinson's patients by transplanting new nerve cells, thereby improving motor function. The therapy is currently in Phase I/IIa clinical trials and has received Fast Track designation and Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration (FDA). The company plans to initiate patient dosing in Phase III clinical trials in the second half of 2027.